Heart Test Labs Files 8-K for Financials

TL;DR

HTLAB filed an 8-K for financials, nothing major disclosed yet.

AI Summary

Heart Test Laboratories, Inc. filed an 8-K on May 22, 2024, reporting events as of May 16, 2024. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates that Heart Test Laboratories, Inc. is providing updated financial information or exhibits to the SEC, which is standard for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• Heart Test Laboratories, Inc. (company) — Registrant
• May 16, 2024 (date) — Date of earliest event reported
• May 22, 2024 (date) — Date of report
• Texas (location) — State of incorporation
• 550 Reserve Street, Suite 360 (address) — Principal Executive Offices
• Southlake, Texas (address) — Principal Executive Offices
• 76092 (zip_code) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — id price of the Company's common stock, $0.001 par value per share (the "Common Stock"
• $1 — ment to maintain a minimum bid price of $1 per share (the "Minimum Bid Price Requi
• $0.10 — Common Stock had a closing bid price of $0.10 or less for at least ten consecutive tr

Filing Documents

• hscs-20240516.htm (8-K) — 53KB
• 0000950170-24-063494.txt ( ) — 193KB
• hscs-20240516.xsd (EX-101.SCH) — 45KB
• hscs-20240516_htm.xml (XML) — 6KB

01

Item 8.01 Other Events. On May 17, 2024, Heart Test Laboratories, Inc. (the "Company") received a notice from the Listing Qualification Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that Nasdaq's previously disclosed delisting action has been stayed pending a final written decision by a Nasdaq Hearing Panel (the "Panel") subsequent to the Company's appeal at an oral hearing scheduled to be held on June 27, 2024, as a result of the Company timely appealing the Staff's delisting determination to the Panel and filing a hearing request with Nasdaq on May 16, 2024. Pending the final written decision by the Panel, the Company's securities will continue to be listed on the Nasdaq Capital Market. As previously reported, on May 17, 2024, the Company implemented a 1-for-100 reverse split of its common stock. Accordingly, at the Panel hearing, the Company intends to present information to show that the Company believes it has regained compliance with both the Low Priced Stocks Rule and the Minimum Bid Price Requirement (each as defined below). In the interim, the Company's common stock and the Company's public warrants will continue to trade on Nasdaq under the symbols "HSCS" and "HSCSW", respectively, at least pending the ultimate conclusion of the hearing process. While the Company believes that it has regained compliance with the Low Priced Stocks Rule, the Minimum Bid Price Requirement and the other Nasdaq continued listing requirements, there can be no assurance that the Company's appeal will be successful or that the Company will otherwise be in compliance with the other Nasdaq listing rules or remain listed on Nasdaq. As previously reported, on August 2, 2023, Heart Test Laboratories, Inc. (the "Company") received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock, $0.001 par value per share (the "Common Stock"), for the

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K (this "Current Report") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this Current Report include, without limitation, statements regarding the Company's intent or ability to regain compliance with the Minimum Bid Price Rule and/or the Low Priced Stocks Rule, the outcome of the Nasdaq hearing and appeal process, and the anticipated actions by the Staff and the Company's responses and their anticipated outcome, and the ability for the Company's common stock and public warrants to remain listed on Nasdaq. Any forward-looking statements in this Current Report are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 19, 2023, as well as discussions of potential risks, uncertainties and other important factors in any subsequent Company filings with the SEC. All information in this Current Report is as of the date of the filing; the Company undertakes no duty to update this information unless required by law.

01 Exhibits

Item 9.01 Exhibits. Exhibit No. Description Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEART TEST LABORATORIES, INC. Date: May 22, 2024 By: /s/ Andrew Simpson Name: Title: Andrew Simpson President, Chief Executive Officer, and Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR